LT4243928T - Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui - Google Patents

Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui

Info

Publication number
LT4243928T
LT4243928T LTEPPCT/EP2021/081236T LTEP2021081236T LT4243928T LT 4243928 T LT4243928 T LT 4243928T LT EP2021081236 T LTEP2021081236 T LT EP2021081236T LT 4243928 T LT4243928 T LT 4243928T
Authority
LT
Lithuania
Prior art keywords
cancer
treatment
dosage regime
gdf15 antibody
gdf15
Prior art date
Application number
LTEPPCT/EP2021/081236T
Other languages
English (en)
Lithuanian (lt)
Inventor
Eugen Leo
Markus Haake
Jörg WISCHHUSEN
Virginie LE BRUN
Susanne JÖRG
Manfred Rüdiger
Original Assignee
Catalym Gmbh
Julius-Maximilians-Universität Würzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalym Gmbh, Julius-Maximilians-Universität Würzburg filed Critical Catalym Gmbh
Publication of LT4243928T publication Critical patent/LT4243928T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/EP2021/081236T 2020-11-10 2021-11-10 Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui LT4243928T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20206801 2020-11-10
EP21175107 2021-05-20
EP21196910 2021-09-15
PCT/EP2021/081236 WO2022101263A1 (en) 2020-11-10 2021-11-10 Anti-gdf15 antibody and a dosage regimen for the treatment of cancer

Publications (1)

Publication Number Publication Date
LT4243928T true LT4243928T (lt) 2026-06-10

Family

ID=78500639

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2021/081236T LT4243928T (lt) 2020-11-10 2021-11-10 Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui

Country Status (17)

Country Link
US (3) US20240043517A1 (cg-RX-API-DMAC7.html)
EP (2) EP4778537A2 (cg-RX-API-DMAC7.html)
JP (1) JP7879142B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230107309A (cg-RX-API-DMAC7.html)
AU (1) AU2021376864A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200687A1 (cg-RX-API-DMAC7.html)
DK (1) DK4243928T3 (cg-RX-API-DMAC7.html)
ES (1) ES3071749T3 (cg-RX-API-DMAC7.html)
FI (1) FI4243928T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260635T1 (cg-RX-API-DMAC7.html)
IL (1) IL302646A (cg-RX-API-DMAC7.html)
LT (1) LT4243928T (cg-RX-API-DMAC7.html)
PL (1) PL4243928T3 (cg-RX-API-DMAC7.html)
RS (1) RS68123B1 (cg-RX-API-DMAC7.html)
SI (1) SI4243928T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600256T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022101263A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021111636A1 (ja) 2019-12-06 2021-06-10 大塚製薬株式会社 抗gdf15抗体
LT4243928T (lt) 2020-11-10 2026-06-10 Catalym Gmbh Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui
EP4584293A1 (en) 2022-09-08 2025-07-16 CatalYm GmbH Anti-gdf15 antibody used in a combination treatment of specific patient groups and a dosage regimen for the treatment of cancer
WO2024126808A1 (en) 2022-12-16 2024-06-20 Catalym Gmbh Anti-gdf 15 antibody for neoadjuvant therapy of cancer
CN116462757A (zh) 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
CA2372119A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
US20070128636A1 (en) 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN101896192A (zh) 2007-10-09 2010-11-24 圣文森特医院悉尼有限公司 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
WO2009150256A1 (en) 2008-06-13 2009-12-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Markers for predicting response and survival in anti-egfr treated patients
CA2737636A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
CA2737597C (en) 2008-10-16 2017-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
EP2388594A1 (en) 2010-05-17 2011-11-23 Roche Diagnostics GmbH GDF-15 based means and methods for survival and recovery prediction in acute inflammation
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
EP2506015A1 (en) 2011-04-01 2012-10-03 Universität Regensburg A prognostic and therapeutic signature for malignant melanoma
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
AU2013322628B2 (en) 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
ES3066738T3 (en) 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
US11021752B2 (en) 2013-03-15 2021-06-01 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
ES2712201T3 (es) 2014-01-28 2019-05-09 Hoffmann La Roche Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B
PT3134123T (pt) 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
PT3653644T (pt) 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
EP3851122A1 (en) * 2014-09-25 2021-07-21 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
EP3073268A1 (en) 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
EP3356827B1 (en) 2015-10-02 2023-12-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
KR102722730B1 (ko) * 2015-10-02 2024-10-25 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 인간 증식 및 분화 인자 15 (gdf-15)의 저해제와 면역 체크포인트 차단제를 이용한 병용 요법
US11072657B2 (en) 2015-11-18 2021-07-27 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
JP7138567B2 (ja) * 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子15に対する抗体およびそれらの使用
CN112912395B (zh) 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法
US20230212274A1 (en) 2020-02-21 2023-07-06 The Children's Medical Center Corporation Method for treating asthma or allergic disease
CN114560938B (zh) 2020-03-30 2023-05-23 中国人民解放军第四军医大学 抗gdf15中和性单克隆抗体及其应用
LT4243928T (lt) 2020-11-10 2026-06-10 Catalym Gmbh Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui

Also Published As

Publication number Publication date
WO2022101263A1 (en) 2022-05-19
EP4243928A1 (en) 2023-09-20
EP4243928B1 (en) 2026-04-22
SMT202600256T1 (it) 2026-07-16
US20240043517A1 (en) 2024-02-08
EP4778537A2 (en) 2026-07-22
HRP20260635T1 (hr) 2026-06-19
JP7879142B2 (ja) 2026-06-23
ES3071749T3 (en) 2026-06-25
FI4243928T3 (fi) 2026-06-04
SI4243928T1 (sl) 2026-07-31
US12497447B2 (en) 2025-12-16
AU2021376864A1 (en) 2023-06-29
DK4243928T3 (da) 2026-05-26
JP2023548430A (ja) 2023-11-16
CA3200687A1 (en) 2022-05-19
US20250282858A1 (en) 2025-09-11
PL4243928T3 (pl) 2026-08-03
RS68123B1 (sr) 2026-06-30
IL302646A (en) 2023-07-01
KR20230107309A (ko) 2023-07-14
US20260055172A1 (en) 2026-02-26